PTC Therapeutics (PTCT) Q1 2026 earnings summary

Executive summary

• Achieved record Q1 2026 product revenue of $226 million, driven by Sephience's strong global launch and mature product contributions, supporting an increase in full-year revenue guidance.

• Net product revenue rose 47% year-over-year, with Sephience contributing $124.6–$125 million and robust U.S. and international uptake.

• Collaboration and license revenue dropped sharply due to the absence of the prior year’s $1.0 billion Novartis upfront payment for the votoplam HD program.

• Positive interim results from votoplam Huntington's disease program and progress on vatiquinone and early-stage pipeline assets.

• Net loss for the quarter was $2.8 million, compared to net income of $866.6 million in the prior year, mainly due to the absence of large one-time license revenue.

Financial highlights

• Total Q1 2026 revenue was $273 million, with product revenue up 47% year-over-year from $153 million in Q1 2025.

• Sephience net product revenue reached $124.6–$125 million, DMD franchise $81 million (Translarna $59 million, EMFLAZA $21.5–$22 million), and Evrysdi royalty revenue $46.8–$47 million.

• Non-GAAP R&D expense was $89.7–$90 million, down from $100 million year-over-year; non-GAAP SG&A expense was $73.9–$74 million, up slightly from $72 million.

• Cash, cash equivalents, and marketable securities totaled $1.89 billion as of March 31, 2026.

• Operating expenses increased to $227.6 million, up from $205.9 million year-over-year, with higher cost of sales and amortization.

Outlook and guidance

• 2026 full-year product revenue guidance raised to $750–$850 million, total revenue to $1.08–$1.18 billion.

• Expect commercial sales of Sephience in up to 30 countries by year-end, with U.S. as primary near-term growth driver.

• Management expects continued significant expenses for commercialization and clinical development, especially for Sephience and ongoing pipeline programs.

• Cash flows from product sales, Novartis milestone payments, and existing liquidity are expected to fund operations for at least the next twelve months.

• A $50 million milestone from Novartis was triggered in April 2026 with the start of a Phase III trial for votoplam.